Vector-Based RNAi Market

Vector-based RNAi (RNA interference) offers a system of treatment and disease management to decrease the inhibition of gene translation or expression, as well as it neutralizes the targeted mRNA molecules. Vector-based RNAi plays very important in cancer treatment,cancer is the top second cause of death across the globe. As well as a new development in vector-based RNAi such as small interfering RNAs (siRNA) and microRNAs (miRNA) can escalate the vector-based RNAi market growth. The challenging situation of FDA approval affecting on a number of new drugs launch, for instance, 2015 (41 drugs), while in 2016 (19 drugs) which are very less as compared with the previous year.
Vector-Based RNAi Market aims to provide a comprehensive presentation of the global market for Vector-Based RNAi, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Vector-Based RNAi. Vector-Based RNAi Market contains market size and forecasts of Vector-Based RNAi in global, including the following market information:
Global Vector-Based RNAi Market Revenue, 2018-2023, 2024-2032, ($ millions)
Global Vector-Based RNAi Market Sales, 2018-2023, 2024-2032, (K Units)
Global top five Vector-Based RNAi companies in 2022 (%)
The global Vector-Based RNAi market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million.
siRNA Design Segment to Reach $ Million by 2029, with a % CAGR in next six years.
The global key manufacturers of Vector-Based RNAi include Merck & Co., Phio Pharmaceutical, Quark Pharmaceuticals, Thermo Fisher Scientific, Silence Therapeutics, Qiagen NV, Ionis Pharmaceutical, Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals, etc. in 2022, the global top five players have a share approximately % in terms of revenue.
We surveyed the Vector-Based RNAi manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Vector-Based RNAi Market, by Type, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Vector-Based RNAi Market Segment Percentages, by Type, 2022 (%)
siRNA Design
siRNA Vectors
Custom siRNA Construction
Global Vector-Based RNAi Market, by Application, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Vector-Based RNAi Market Segment Percentages, by Application, 2022 (%)
Hospitals
Speciality Clinics
Global Vector-Based RNAi Market, By Region and Country, 2018-2023, 2024-2032 ($ Millions) & (K Units)
Global Vector-Based RNAi Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Vector-Based RNAi revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Vector-Based RNAi revenues share in global market, 2022 (%)
Key companies Vector-Based RNAi sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Vector-Based RNAi sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Merck & Co.
Phio Pharmaceutical
Quark Pharmaceuticals
Thermo Fisher Scientific
Silence Therapeutics
Qiagen NV
Ionis Pharmaceutical
Dicerna Pharmaceuticals
Arrowhead Pharmaceuticals
Arcturus Therapeutics
Alnylam Pharmaceuticals
Outline of Major Chapters:
Chapter 1: Introduces the definition of Vector-Based RNAi, market overview.
Chapter 2: Global Vector-Based RNAi market size in revenue and volume.
Chapter 3: Detailed analysis of Vector-Based RNAi manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Vector-Based RNAi in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Vector-Based RNAi capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.